DAX23.951 -2,1%Est505.828 -1,8%MSCI World4.343 -0,1%Top 10 Crypto10,03 -1,1%Nas26.225 -1,5%Bitcoin68.023 -2,1%Euro1,1625 -0,4%Öl109,4 +3,5%Gold4.538 -2,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Infineon 623100 SAP 716460 Siemens Energy ENER6Y Lufthansa 823212 Deutsche Telekom 555750 Apple 865985 NEL ASA A0B733 Münchener Rückversicherungs-Gesellschaft 843002 Allianz 840400 Microsoft 870747 Intel 855681 Micron Technology 869020 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Unter 24.000 Punkten: DAX geht tiefrot ins Wochenende -- Wall Street letztlich schwach -- Trump handelte Aktien von NVIDIA & Co. vor China-Reise -- Microsoft, Figma, NEL, Infineon, freenet im Fokus
Top News
DAX in KW 20: Diese Aktien gehörten zu den Gewinnern und Verlierern DAX in KW 20: Diese Aktien gehörten zu den Gewinnern und Verlierern
Apple-Aktie nach Rekordhoch: Warum der Monat Juni entscheidend werden könnte Apple-Aktie nach Rekordhoch: Warum der Monat Juni entscheidend werden könnte
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Neurocrine Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
136,32 EUR -0,64 EUR -0,47 %
BMN
158,46 USD -0,60 USD -0,38 %
BTT
finanzen.net zero
Neurocrine Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.13,94 Mrd. EUR

KGV30,38Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN900964

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS64125C1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNBIX

Neurocrine Biosciences Aktien News

DatumMeistgelesen
ZacksNeurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates
ZacksNeurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
ZacksIs the Options Market Predicting a Spike in Neurocrine Biosciences Stock?
Wer­bungNeurocrine Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BenzingaForecasting The Future: 10 Analyst Projections For Neurocrine Biosciences
ZacksNeurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
BenzingaNeurocrine Biosciences Q4 Earnings Assessment
ZacksNeurocrine Biosciences to Report Q4 Earnings: What's in the Cards?
ZacksNeurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
BenzingaWhat Analysts Are Saying About Neurocrine Biosciences Stock
PR NewswireNeurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
PR NewswireNeurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
PR NewswireNeurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
PR NewswireNeurocrine Biosciences to Host R&D Day on December 16
PR NewswireNeurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences
PR NewswireNeurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
ZacksNeurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
PR NewswireNeurocrine Biosciences Reports Third Quarter 2025 Financial Results
ZacksAre You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice
BenzingaWhat 13 Analyst Ratings Have To Say About Neurocrine Biosciences
ZacksNeurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
BenzingaDemystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews
PR NewswireNeurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
PR NewswireNeurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
PR NewswireNeurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
PR NewswireNeurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Dis...
PR NewswireNeurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
BenzingaWhere Neurocrine Biosciences Stands With Analysts
PR NewswireNeurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
BenzingaBreaking Down Neurocrine Biosciences: 12 Analysts Share Their Views
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in September
PR NewswireNeurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
BenzingaThe Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts
ZacksNeurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
PR NewswireNeurocrine Biosciences Reports Second Quarter 2025 Financial Results
ZacksNeurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
PR NewswireNeurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
PR NewswireNeurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Co...
PR NewswireNeurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting

Neurocrine Biosciences News

Neurocrine Biosciences News: auf dieser Seite finden Sie alle Neurocrine Biosciences News und Nachrichten zur Neurocrine Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Neurocrine Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Neurocrine Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.